

LETTER TO THE EDITOR
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights

Clonal selection is one of the mechanisms leading to therapy-related myeloid neoplasms (TRMN). A preexisting somatic mutation in hematopoietic stem cells [defined as clonal hematopoiesis (CH)] emerging under the pressure of chemotherapy or radiotherapy treatment could ultimately lead to TRMN development.¹ Most of the mutations identified in TRMN, such as *TP53* and *PPM1D*, belong to the DNA damage response (DDR) pathway and are known to confer a dismal prognosis. The poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising results in several cancers, especially in ovarian cancers (OC).² Recently, Morice et al.³ confirmed in a meta-analysis an increased risk of TRMN after PARPi administration. In this context, we aimed to describe the prevalence and evolution of CH and TRMN following PARPi treatment in patients treated for OC, with the goal of better understanding the molecular mechanisms underlying hematological disease development (Patients and methods and NGS Results, available at <https://doi.org/10.1016/j.annonc.2021.04.05>).

Firstly, we retrospectively identified, with the help of the UNIHEM group of Unicancer, 20 patients with myelodysplastic syndrome (11; 55%) or acute myeloid leukemia (AML) (9; 45%) occurring during or after PARPi administration (Supplementary Table S1, available at <https://doi.org/10.1016/j.annonc.2021.04.015>). Median duration of PARPi treatment was 17 months (3-57 months). TRMN-PARPi occurred 2 years (range: 0.4-4.8 years) after PARPi initiation and 1.6 months (range: 0.4-17.6 months) after PARPi discontinuation (Figure 1A). All patients had unfavorable karyotypes, of which 19 of 20 (95%) had complex karyotypes; 10 of 12 (83%) harbored next-generation sequencing (NGS) mutations in the DDR genes. Despite 11 (55%) patients with OC in complete remission, median overall survival was 4.3 months (95% confidence interval 2.1 months to not reached). Secondly, we identified 36 OC patients with or without PARPi maintenance treatment and free of hematological disease, to compare occurrence of CH. Median duration of PARPi treatment was 11.2 months (range: 0.4-45.8 months) and Median time between PARPi beginning and NGS, months (range) 8.5 (1.1-15.6). No significant differences in terms of patient characteristics were found between the two groups. CH was found in 14 of 18 patients (78%) in the PARPi group compared to 7 of 18 patients without PARPi maintenance (39%) ($P = 0.018$, Figure 1B; Supplementary Table S2, available at <https://doi.org/10.1016/j.annonc.2021.04.015>). Twelve (67%) patients treated with PARPi harbored CH mutations in the DDR pathway (Figure 1C) compared to 3 of 18 patients without PARPi maintenance (16.7%)

($P = 0.002$). Lastly, we sequenced nine paired specimens pre- and post-PARPi treatment (Figure 1D for TRMN; Supplementary Figure S1, available at <https://doi.org/10.1016/j.annonc.2021.04.015> for CH) showing that mutations emerged or expanded during PARPi treatment.

Predicting AML was considered hitherto impossible. The democratization of NGS and the description of CH have changed this paradigm. The clinical abruptness of AML contrasts with the biological step-by-step development of the disease. Some patients may have years before a founding clone at a low level, emerging and leading to AML, especially *TP53* mutations.⁴ CH incidence is ~38% in gynecological cancer with an enrichment in DDR gene mutations.⁵ Our data support the hypothesis that PARPi therapy may act by exerting a selective pressure that boosts clonal expansion, especially *TP53* and *PPM1D* mutations. The clinical benefit of PARPi treatment as a maintenance therapy for OC patients is not questionable but our data raise the question of identification and potential preventive strategies in patients who are considered at high risk of developing TRMN.

J. E. Martin¹, S. Khalife-Hachem¹, T. Grinda^{1,2}, M. Kfoury^{2,3}, S. Garciaz^{4,5}, F. Pasquier^{1,6}, J. Vargaftig⁷, M. Uzunov⁸, A. Belhabri⁹, S. Bertoli¹⁰, S. Cotteret¹¹, V. Vergé¹¹, A. Renneville⁶, F. Rosselli¹², I. Antony-Debre⁶, E. Rouleau¹¹, F. Salviat¹³, O. Caron^{2,14}, S. Delaloge^{2,14}, P. Pautier², G. Etienne¹⁵, C. Recher¹⁰, N. Vey^{4,5}, S. De Botton¹, A. Leary^{2,3,14}, C. Marzac¹¹ & J. B. Micol^{1,6,14*}

¹Departments of ¹Hematology;

²Oncology, Gustave Roussy,

Villejuif, and Paris Saclay University, Orsay

³INSERM U981, Villejuif;

⁴Department of Hematology, Institut Paoli Calmettes, Marseille;

⁵Cancer Research Center of Marseille, INSERM U1068, Aix-Marseille University, Marseille;

⁶INSERM U1287, Gustave Roussy, Université Paris-Saclay, Villejuif;

⁷Department of Hematology, Institut Curie, Paris;

⁸Department of Hematology, Hôpital Pitié-Salpêtrière, Paris;

⁹Department of Oncology, Centre Leon Berard, Lyon;

¹⁰Hematology Department,

Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse;

¹¹Department of Biology, Gustave Roussy, Université Paris-Saclay, Villejuif;

¹²CNRS UMR9019, Gustave Roussy Institute, Université Paris-Saclay, Villejuif;

¹³Department of Biostatistics, Université Paris-Saclay, Villejuif;

¹⁴Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif;




Figure 1. Clinical and molecular characteristics of therapy-related myeloid neoplasm and clonal hematopoiesis of patients treated with PARP inhibitor.

(A) Time between OC diagnosis, PARPi treatment, and TRMN; (B) gene mutations in OC patients without TRMN treated with or without PARPi; (C) DDR gene mutation CH in OC patients following PARPi treatment; and (D) sequential NGS samples from cancer diagnosis to TRMN-PARPi diagnosis.

CH, clonal hematopoiesis; DDR, DNA damage response; NGS, next-generation sequencing; OC, ovarian cancer; PARPi, poly(ADP-ribose) polymerase inhibitors; t-AML, therapy-related acute myeloid leukemia; t-MDS, therapy-related myelodysplastic syndrome; TRMN, therapy-related myeloid neoplasms; trt, treatment; VAF, variant allele frequency.

¹⁵Department of Hematology, Institute Bergonie, Hôpital Haut-Leveque, Pessac, France
(*E-mail: Jeanbaptiste.MICOL@gustaveroussy.fr).

Available online xxx

© 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

<https://doi.org/10.1016/j.annonc.2021.04.015>

FUNDING

This work was supported by a grant from Association Laurette Fugain [grant number ALF 2019/11] and French National Cancer Institute (INCa) PAIR gyneco grant [grant number 12-017].

DISCLOSURE

JBM received honoraria from AbbVie, Jazz Pharmaceuticals, and Astellas outside the submitted work. CM received honoraria from Astellas outside the submitted work. AL reports fees to her institution for consulting from AstraZeneca, Clovis, GlaxoSmithKline, Biocad, Ability Pharma, Merck Serono, Tesaro, Merck Sharp & Dohme, Seattle Genetics, GamaMabs Pharma, and Gritstone Oncology; grants from Inivata and Sanofi; personal fees for consulting from Biocad, Gridstone Oncology, and Seattle Genetics;

and non-financial support from AstraZeneca, Roche, Clovis, and Tesaro, outside the submitted work. SDB received honoraria from Agios, Celgene, Forma Therapeutics, AbbVie, Astellas, Daichi, Novartis, Pfizer, and Jazz Pharmaceuticals and has received research funding from Agios and Forma Therapeutics outside the submitted work. SD received honoraria from Pfizer, AstraZeneca, and Roche Genentech and has received research funding from Novartis, Pfizer, AstraZeneca, Roche Genentech, Lilly, Puma, Myriad, Orion, Amgen, Sanofi, Genomic Health, GE, Servier, MSD, BMS, and Pierre Fabre outside the submitted work. SB received grants from Astellas, Daiichi-Sankyo, Jazz Pharmaceuticals, and Sanofi. CR reported grants from Celgene, Amgen, Novartis, Jazz, AbbVie, Astellas, MaatPharma, Agios, Daiichi-Sankyo, and Roche; personal fees from Incyte, MacroGenics, Otsuka, Janssen, Pfizer, and Takeda; and non-financial support from Sanofi and Gilead outside the submitted work. GE received honoraria from Bristol Myers Squibb, Incyte, Pfizer, and Novartis and non-financial support from Pfizer and Novartis outside the submitted work. All other authors have declared no conflicts of interest.

REFERENCES

- McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. *Nat Rev Cancer*. 2017;17:513-527.

2. Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. *Ann Oncol*. 2019;30:1437-1447.
3. Morice PM, Leary A, Dolladille C, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. *Lancet Haematol*. 2021;8:e122-e134.
4. Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. *Nat Med*. 2018;24:1015-1023.
5. Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. *Cell Stem Cell*. 2017;21:374-382.e4.